85% Of Pharma Companies Confident About Winning War On Counterfeiting

Pharma IQ has just published the results of its Pharmaceutical Anti-Counterfeiting Survey, conducted in October 2011 among 1,000 pharma anti-counterfeiting specialists.

61.5% respondents found that the threat of counterfeit medicines in the next year was more severe than ever and 53.8% admitted that they were planning to increase their budget for investment in the anti-counterfeiting area.

With regard to the anti-counterfeiting technology they were using, only 53% were satisfied with it; over 23% admitted that they weren't content with their current solutions. 84% declared that they were looking to invest in the new ones.

Emerging markets from Asia (especially China) were perceived as the major source of the anti-counterfeit drugs (50%). 21.4% and 21% of respondents indicated internet and organised crime respectively as the major threats for the pharmaceutical market.

Even though the statistics showed that consciousness of the threat of counterfeit medicines was significant, the vast majority of respondents (84.6%) shared their optimism, claiming that they were positive about winning the war on pharmaceutical counterfeits.

The survey was created as a part of the pre-conference research for Pharmaceutical Anti-Counterfeiting, taking place 15-17 February 2011 in Amsterdam. The results helped to shape the agenda and the final speaker line-up. David Shore, Director Global Security Europe from Pfizer will present the case study on successes and best practices in pharmaceutical anti-counterfeiting and Axel Fritz Meyer, Head of Complaint Service and Quality Support from Sanofi-Aventis will showcase the external and internal anti-counterfeiting methodologies to prevent counterfeits.

Other topics pointed out by survey responders that will be discussed at the event include:

    Securing The Pharmaceutical Supply Chain: How Global Standards Enable Traceability And Visibility (Jan Denecker, GS1 Global Office)
    Pharmaceutical Counterfeiting: Assessing The Realities And Handling The Challenges (Andrew Jackson, Novartis)
    Viewing And Using Anti-Counterfeiting As A Strategic Business Opportunity (Mark Davison, Blue Sphere Health Ltd.)
    The Impact Of A New Legal Framework (Monika Derecque-Pois, GIRP)

    To find out more, please visit http://www.pharmaceuticalanticounterfeiting.com, email enquire@iqpc.co.uk or call 44 (0) 2073689421.

Source:
Pharma IQ